169 related articles for article (PubMed ID: 35743549)
1. Pharmacokinetics and Clinical Implications of Two Non-Tablet Oral Formulations of L-Thyroxine in Patients with Hypothyroidism.
Trimboli P; Mouly S
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743549
[TBL] [Abstract][Full Text] [Related]
2. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine.
Antonelli A; Elia G; Ragusa F; Paparo SR; Cavallini G; Benvenga S; Ferrari SM; Fallahi P
Front Endocrinol (Lausanne); 2021; 12():633587. PubMed ID: 33790863
[TBL] [Abstract][Full Text] [Related]
3. The administration of L-thyroxine as soft gel capsule or liquid solution.
Vita R; Fallahi P; Antonelli A; Benvenga S
Expert Opin Drug Deliv; 2014 Jul; 11(7):1103-11. PubMed ID: 24896369
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update.
Fallahi P; Ferrari SM; Ruffilli I; Ragusa F; Biricotti M; Materazzi G; Miccoli P; Antonelli A
Expert Opin Drug Deliv; 2017 May; 14(5):647-655. PubMed ID: 27552635
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence and the use of new pharmaceutical formulations: the case of levothyroxine.
Scavone C; Sportiello L; Cimmaruta D; Sullo MG; Vitelli B; Rafaniello C; Fossati T; Rossi F
Minerva Endocrinol; 2016 Jun; 41(2):279-89. PubMed ID: 27015567
[TBL] [Abstract][Full Text] [Related]
6. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.
Vita R; Saraceno G; Trimarchi F; Benvenga S
Endocrine; 2013 Feb; 43(1):154-60. PubMed ID: 22932947
[TBL] [Abstract][Full Text] [Related]
7. Liquid and softgel capsules of l-thyroxine results lower serum thyrotropin levels more than tablet formulations in hypothyroid patients.
Benvenga S
J Clin Transl Endocrinol; 2019 Dec; 18():100204. PubMed ID: 31844631
[TBL] [Abstract][Full Text] [Related]
8. l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism.
Benvenga S; Capodicasa G; Perelli S
Front Endocrinol (Lausanne); 2017; 8():321. PubMed ID: 29209276
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule.
Vita R; Benvenga S
Endocr Pract; 2014 Mar; 20(3):e38-41. PubMed ID: 24246350
[TBL] [Abstract][Full Text] [Related]
11. L-T4 Therapy in Enteric Malabsorptive Disorders.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():626371. PubMed ID: 33708175
[TBL] [Abstract][Full Text] [Related]
12. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.
Fallahi P; Ferrari SM; Antonelli A
Endocrine; 2016 Jun; 52(3):597-601. PubMed ID: 26721663
[TBL] [Abstract][Full Text] [Related]
13. IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.
Fallahi P; Ferrari SM; Antonelli A
Endocr Pract; 2017 Feb; 23(2):170-174. PubMed ID: 27849377
[TBL] [Abstract][Full Text] [Related]
14. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series.
Fallahi P; Ferrari SM; Ruffilli I; Antonelli A
BMC Gastroenterol; 2016 Feb; 16():22. PubMed ID: 26965518
[TBL] [Abstract][Full Text] [Related]
15. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance.
Jojima T; Shinzawa T; Ohira E; Sakurai S; Tomaru T; Iijima T; Kogai T; Usui I; Aso Y
Endocr J; 2022 Aug; 69(8):941-945. PubMed ID: 35249899
[TBL] [Abstract][Full Text] [Related]
16. New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?
Nagy EV; Perros P; Papini E; Katko M; Hegedüs L
Thyroid; 2021 Feb; 31(2):193-201. PubMed ID: 33003978
[No Abstract] [Full Text] [Related]
17. Treatment of congenital hypothyroidism: comparison between L-thyroxine oral solution and tablet formulations up to 3 years of age.
Vigone MC; Ortolano R; Vincenzi G; Pozzi C; Ratti M; Assirelli V; Vissani S; Cavarzere P; Mussa A; Gastaldi R; Di Mase R; Salerno M; Street ME; Trombatore J; Weber G; Cassio A
Eur J Endocrinol; 2021 Nov; 186(1):45-52. PubMed ID: 34714772
[TBL] [Abstract][Full Text] [Related]
18. Levothyroxine soft capsules demonstrate bioequivalent pharmacokinetic exposure with the European reference tablets in healthy volunteers under fasting conditions.
Al-Numani D; Scarsi C; Ducharme MP
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):135-43. PubMed ID: 26754305
[TBL] [Abstract][Full Text] [Related]
19. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia.
Morini E; Catalano A; Lasco A; Morabito N; Benvenga S
Endocrine; 2019 Sep; 65(3):569-579. PubMed ID: 30919287
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?
Castellana M; Castellana C; Giovanella L; Trimboli P
Endocrine; 2020 Feb; 67(2):281-290. PubMed ID: 31953721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]